Icon times
Rossari Biotech delivers strong performance in Q2FY2022 triggered by uptick in all the segment & recent acquisitions | Q2 FY22 4 Point Result Analysis & Earning Call

Rossari Biotech delivers strong performance in Q2FY2022 triggered by uptick in all the segment & recent acquisitions | Q2 FY22 4 Point Result Analysis & Earning Call

Published on 12 November 2021 Views 13 Comments 0
The company has delivered strong topline & bottom line growth aided by strong growth momentum across all segments as well as recent acquisitions. But Margins tumbled due to extremely heavy inflationary pressure across segments

Please find attached for detailed analysis.
Attachments
File Name
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs 7499/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

LATEST UPDATE

premium Premium
free Free
Read More

REPORTS


Corporate Action News

Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya